Hologic today announced plans to release its first quarter fiscal 2009 operating results on Monday, February 2, 2009 after market close. In conjunction with the release, management will host a conference call on Monday, February 2, 2009 at 5:00 p.m. (eastern).

BEDFORD, Mass. (December 5, 2008) - Hologic today announced that Jack Cumming, Chairman and Chief Executive Officer, will be presenting at the J.P. Morgan 27th Annual Healthcare Conference being held January 12, 2009, at the Westin St. Francis Hotel in San Francisco, CA.

Hologic today announced the Company will host a meeting for members of the investment community who will be attending the RSNA (Radiological Society of North America) trade show in Chicago.

Hologic today announced the results of the Cervista HPV high-risk pivotal clinical trial. The Cervista HPV high-risk test is currently under review by the FDA in the U.S. and is expected to be launched in the European Union (EU) early in 2009. The clinical and analytical performance of Cervista HPV high-risk test results are scheduled to be presented at the European Research Organization on Genital Infection and Neoplasia (Eurogin) HPV conference in Nice, France on Saturday November 15th 2008. Due to an early publication of the abstract by the conference organizers, Hologic has brought forward the release of this data.

Hologic today announced that it has received CE Mark approval for the Celero® vacuum-assisted, spring loaded core biopsy device. Celero is the first U.S. DA-cleared vacuum-assisted core biopsy device for the breast ultrasound market. The company has also received CE Mark approval for the CeleroMark™ and CeleroMark-2S biopsy site identifiers, as well as the Celero Intro-12 introducer, clearing the way for sales in the European Union (EU) and all countries recognizing the CE Mark. Some of the unique features of the Celero device are patented.

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Oppenheimer 4th Annual Mid and Small Cap 'Best Ideas' Conference being held November 18 - 19, 2008, at the Millennium Broadway Hotel in New York, NY.

Hologic today announced plans to release its fourth quarter and fiscal 2008 operating results on Tuesday, November 11, 2008 after market close. In conjunction with the release, management will host a conference call on Tuesday, November 11, 2008 at 5:00 p.m. (eastern).

Hologic today announced the positive results of a study to be published October 16 ,2008 in the New England Journal of Medicine involving its R2 Computer-Aided Detection (CAD) system1. The study was published in the on-line version of the Journal yesterday (http://content.nejm.org/cgi/content/full/NEJMoa0803545). In this prospective, multi-center clinical trial, researchers compared the cancer detection rate for single reading of screening mammograms with CAD input versus double reading without CAD support.

Hologic today announced that it has received Food and Drug Administration (FDA) clearance for the R2 Quantra volumetric breast density assessment tool.

Hologic today announced that a four-year analysis of the Hologic MammoSite radiation therapy system has found that breast cancer recurrence rates following the delivery of accelerated partial breast irradiation with the MammoSite system continue to be comparable to the rates reported with standard radiation therapy. The study was presented by Dr. Peter Beitsch of Medical City Dallas Hospital at the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in September. Dr. Beitsch and his colleagues analyzed data from patients enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial.

Hologic today announced that Jack Cumming, Chairman & CEO, will be presenting at the Merrill Lynch Global Pharmaceutical Conference being held September 16 - 18, 2008, at the Merrill Lynch Financial Centre in London.

Hologic today announced it is the first diagnostic medical device manufacturer to receive U.S. Food and Drug Administration clearance to incorporate the World Health Organization (WHO) FRAX™ 10-year fracture risk calculator into its bone densitometer systems.

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Morgan Stanley Global Healthcare Unplugged Conference being held September 9, 2008, at the Grand Hyatt Hotel in New York, NY.

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Canaccord Adams 28th Annual Global Growth Conference being held August 12 - 14, 2008, at the InterContinental Hotel in Boston, MA.

Hologic today announced the successful completion of the tender offer by its direct wholly-owned subsidiary, Thunder Tech Corp., for all outstanding shares of Third Wave Technologies, Inc. (Nasdaq: TWTI) at a price of $11.25 per share in cash.

Hologic today announced plans to release its third quarter fiscal 2008 operating results on Wednesday, July 30, 2008 after market close. In conjunction with the release, management will host a conference call on Thursday, July 31, 2008 at 9:00 a.m. (eastern).

Hologic and Third Wave Technologies today jointly announced the expiration of the initial offering period of the tender offer by its wholly-owned subsidiary Thunder Tech Corp. (the “Purchaser”) for all outstanding shares of common stock of Third Wave. The initial offering period expired, as scheduled, at 12:00 midnight, New York City time, on Wednesday, July 16, 2008.

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Collins Stewart Fourth Annual Growth Conference being held July 8 – 10, 2008, at the Mandarin Oriental Hotel in New York, NY.

Hologic today announced that the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), on June 24, 2008, in connection with Hologic’s previously announced tender offer for all of the outstanding shares of the common stock of Third Wave Technologies, Inc. (Nasdaq: TWTI). The early termination of the waiting period under the HSR Act satisfies the conditions to the tender offer related to the expiration or termination of any applicable waiting periods under the HSR Act and other state and foreign regulatory laws relating to the restraint of trade or lessening of competition. The tender offer remains subject to certain other conditions described in the Offer to Purchase.

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Jefferies 2nd Annual Healthcare Conference being held June 24 - 26, 2008, at the Mandarin Oriental Hotel in New York, NY.

Hologic announced today that it has signed a definitive agreement to acquire Third Wave Technologies, Inc. (NASDAQ: TWTI) for a purchase price of $11.25 per share, or approximately $580 million in value, representing an approximately 24% premium to Third Wave’s average trading price over the last three months. The Boards of Directors of both companies unanimously approved the transaction in which Hologic is to acquire 100% of Third Wave’s stock in a cash tender offer to be followed by a merger to acquire any untendered shares. The transaction, completion of which is anticipated in the third calendar quarter of 2008, is expected to be modestly dilutive to Hologic’s adjusted earnings per share in the first full year after closing, and increasingly accretive thereafter.

Hologic today announced that Rob Cascella, President and COO and Glenn Muir, Chief Financial Officer, will be presenting at the Needham Seventh Annual Biotechnology and Medical Technology Conference being held June 11 - 12, 2008, at the New York Palace Hotel in New York, NY.

Hologic today announced that Rob Cascella, President and COO and Glenn Muir, Chief Financial Officer, will be presenting at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference being held June 9 - 12, 2008, at the Ritz-Carlton Hotel in Dana Point, CA.

Hologic today announced that Jack Cumming, Chief Executive Officer will be presenting at the NASDAQ 21st Investor Program being held May 21, 2008 at the Andaz Hotel in London.

Hologic today announced Patrick Sullivan has resigned from his position as a director and Chairman of the Board, effective May 20, 2008. Also effective today, the Board appointed Jack W. Cumming to the position of Chairman. Mr. Cumming will continue as the Company’s Chief Executive Officer.

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Citigroup Investment Research Global Healthcare Conference being held May 21 - 22, 2008, at the Hilton Hotel in New York, NY.

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Bank of America Healthcare Conference being held May 13 - 15, 2008, at the Four Season Hotel in Las Vegas, NV.

Hologic today announced that they have received an order for 17 Selenia™ digital mammography mobile systems, the first order placed under The Netherlands Breast Cancer Screening Tender. The order was placed by the Dutch screening organizations BoBWest and SBBZWN, located in the southwestern part of the country. The company will start installing the systems this Summer.

Hologic today announced that Patrick Sullivan, Executive Chairman, and Glenn Muir, Chief Financial Officer, will be presenting at the Morgan Stanley Global Healthcare Unplugged Conference being held April 30 - May 2, 2008, at the Ritz-Carlton Hotel in Key Biscayne, FL.

Hologic today announced plans to release its second quarter fiscal 2008 operating results on Thursday, May 1, 2008 at 8:00 a.m. (eastern). In conjunction with the release, management will host a conference call on Thursday, May 1, 2008 at 9:00 a.m. (eastern).

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Sun Trust Robinson Humphrey’s 37th Annual Conference being held April 16, 2008, at the Ritz-Carlton Hotel in Buckhead, GA.

Hologic confirmed the previously announced two-for-one stock split, to be effected in the form of a stock dividend. The record date for the stock split was March 21, 2008 and the payment date will be April 2, 2008. On the payment date, the transfer agent will mail certificates representing one additional share for each share held on March 21, 2008 (or otherwise record the ownership of these additional shares). The ex dividend ate for Hologic on the NASDAQ Global Select Market will be April 3, 2008. Hologic stockholders do not need to exchange their current stock certificates or take any other action to receive the split shares.

Hologic today announced that Patrick Sullivan, Executive Chairman and Glenn Muir, Chief Financial Officer, will be presenting at the Bank of America 2008 Smid Cap Conference being held March 26-27, 2008 at the Four Seasons Hotel in Boston, MA.

Hologic today announced that Patrick Sullivan, Executive Chairman, and Glenn Muir, Chief Financial Officer, will be presenting at the Lehman Brothers Eleventh Annual Global Healthcare Conference being held March 18-20, 2008, at Loews Miami Beach Hotel in Miami, Florida.

Hologic today announced that Jack Cumming, Chief Executive Officer, and Glenn Muir, Chief Financial Officer, will be presenting at the Citi 5th Annual Small and Midcap Conference being held March 17-19, 2008, at the Four Seasons Hotel in Las Vegas, Nevada.

Hologic today announced that Patrick Sullivan, Executive Chairman and Glenn Muir, Chief Financial Officer, will be presenting at Susquehanna’s Significant Options in Healthcare Conference being held March 4-5, 2008 at the W Hotel in New York City, NY.

Hologic today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Raymond James & Associates 29th Annual Institutional Investors Conference being held March 2-5, 2008 at the Hyatt Regency Grand Cypress Hotel in Orlando, FL.

Hologic today announced the publication of a study evaluating the Hologic MammoSite® Radiation Therapy System (RTS), one-, two- and three-years after treatment. The study by Frank A. Vicini, M.D., and others, published in the February 15, 2008, issue of Cancer , the peer-reviewed professional journal of the American Cancer Society, reports on treatment efficacy, cosmetic results and toxicities of patients enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial.

Hologic, Inc. today announced the publication of a large scale breast screening trial comparing a single radiologist using computer-aided detection (CAD) to double reading without CAD. The author of the study is Dr. Matthew Gromet of the Breast Imaging Section of Charlotte Radiology, a large imaging practice (approximately 66,000 screening mammograms a year) in Charlotte, North Carolina. The study , published in the on-line version of the American Journal of Roentgenology, the scientific journal of the American Roentgen Ray Society, will appear in the April 2008 issue of the research journal. The study compared the recall rate, sensitivity, positive predictive value, and cancer detection rate for single reading with CAD, versus double reading without CAD. Biopsy and pathology data for positive cases were also compared.

Hologic today announced that Patrick Sullivan, Executive Chairman and Glenn Muir, Chief Financial Officer, will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference being held February 5-7, 2008 at the Grand Hyatt Hotel in New York, NY.

Hologic today announced that its Board of Directors has approved a two-for-one stock split, to be effected in the form of a stock dividend, subject to stockholder approval of a proposed amendment to the Certificate of Incorporation of the Company to increase the number of shares of Common Stock the Company has the authority to issue from 300 million to 750 million shares.

Hologic today announced plans to release its first quarter fiscal 2008 operating results on Thursday, January 31, 2008 at 8:00 a.m. (eastern). In conjunction with the release, management will host a conference call on Thursday, January 31, 2008 at 9:00 a.m. (eastern).

Hologic announced today that it has entered into a definitive agreement pursuant to which it has agreed to sell full U.S. and worldwide rights to Gestiva(TM) (17-alpha hydroxyprogesterone caproate) to KV Pharmaceutical Company upon approval of the pending Gestiva(TM) New Drug Application (the “Gestiva NDA”) by the U.S. Food and Drug Administration (the “FDA”).

Hologic today announced that Jack Cumming, Chief Executive Officer, and Rob Cascella, Chief Operating Officer, will be presenting at the 26th Annual JP Morgan Healthcare Conference being held January 7-10, 2008 at the Westin St. Francis Hotel in San Francisco, CA.

Hologic today announced that Patrick Sullivan, Executive Chairman and Glenn Muir, Chief Financial Officer, will be presenting at the Tenth Annual Needham & Company Growth Conference being held January 8-11, 2008 at the Palace Hotel in New York, NY.